Cellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB - Get Free Report) will post its quarterly earnings results before the market opens on Tuesday, May 14th. Analysts expect Cellectar Biosciences to post earnings of ($0.50) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Cellectar Biosciences (NASDAQ:CLRB - Get Free Report) last posted its earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.07). On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cellectar Biosciences Stock Performance

Cellectar Biosciences stock traded down $0.09 during trading on Wednesday, reaching $3.20. 373,821 shares of the company's stock were exchanged, compared to its average volume of 1,553,144. The company's 50-day moving average is $3.58 and its two-hundred day moving average is $3.14. Cellectar Biosciences has a 52-week low of $1.33 and a 52-week high of $4.45. The firm has a market cap of $114.72 million, a price-to-earnings ratio of -1.03 and a beta of 0.99.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Oppenheimer reiterated an "outperform" rating and set a $12.00 target price (up from $11.00) on shares of Cellectar Biosciences in a report on Thursday, March 28th. Roth Mkm boosted their target price on shares of Cellectar Biosciences from $20.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, March 28th. Finally, StockNews.com raised shares of Cellectar Biosciences to a "sell" rating in a report on Thursday, March 28th.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.